Nitecapone (cas 116313-94-1) reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats
-
Add time:08/02/2019 Source:sciencedirect.com
Neuropathic pain is caused by damage or malfunctioning of the nervous system. It is fairly common and more resistant to treatment than other types of pain. Since Nitecapone (cas 116313-94-1), an inhibitor of catechol-O-methyl-transferase (COMT), has decreased neuropathic symptoms in diabetic rats, we studied its effects in another model of neuropathic pain, the spinal nerve ligation (SNL) model. Spinal nerves L5–6 were ligated in male Wistar rats under anaesthesia to produce the SNL model of neuropathic pain. Nitecapone (30 mg/kg, i.p.) or vehicle was administered once daily starting either 1 h before or 2 days after surgery and continued for 14–19 days. Threshold for mechanical allodynia was measured with the digital von Frey test and responses to cold stimuli with the acetone test, before surgery and every other day after it 1 h before drug administration.Mechanical and cold allodynia developed in all study groups. Both nitecapone treatments significantly reduced mechanical allodynia and withdrawal thresholds were 80–95% higher compared with the control group. In the acetone test, both nitecapone groups also showed less signs of cold allodynia than the control groups. In nitecapone-naïve animals a single dose of nitecapone also reduced mechanical allodynia on the 14th day after the surgery. Nitecapone reduced the symptoms of neuropathic pain after the SNL, which is in line with the earlier study. Our results suggest that nitecapone and other COMT inhibitors should be studied further in the treatment of neuropathic pain.
We also recommend Trading Suppliers and Manufacturers of Nitecapone (cas 116313-94-1). Pls Click Website Link as below: cas 116313-94-1 suppliers
Prev:The endothelin peptides ET-1, ET-2, ET-3 and SARAFOTOXIN S6B (cas 116303-65-2) are co-mitogenic with platelet-derived growth factor for vascular smooth muscle cells
Next:Antioxidant properties of Nitecapone (cas 116313-94-1) (OR-462)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Pain Behavior and Response Properties of Spinal Dorsal Horn Neurons Following Experimental Diabetic Neuropathy in the Rat: Modulation by Nitecapone (cas 116313-94-1), a COMT Inhibitor with Antioxidant Properties08/11/2019
- [54] Antioxidant activity of Nitecapone (cas 116313-94-1) and its analog OR-1246: Effect of structural modification on antioxidant action08/10/2019
- Inhibition of gastric mucosal laminin receptor by Helicobacter pylori lipopolysaccharide: Effect of Nitecapone (cas 116313-94-1)08/09/2019
- Determination of a catechol-O-methyltransferase inhibitor, Nitecapone (cas 116313-94-1), in human plasma and urine by liquid chromatography08/08/2019
- Protection against alcohol-induced gastric mucosal injury by Nitecapone (cas 116313-94-1)08/07/2019
- Nitecapone (cas 116313-94-1) as an additive to crystalloid cardioplegia in patients who had coronary artery bypass grafting08/06/2019
- Nitecapone (cas 116313-94-1) effect on the synthesis and secretion of gastric sulfomucin08/05/2019
- Role of ascorbate in protection by Nitecapone (cas 116313-94-1) against cardiac ischemia-reperfusion injury08/04/2019
- Antioxidant properties of Nitecapone (cas 116313-94-1) (OR-462)08/03/2019